We first compared the relative expression (FC) of TIGIT, PD-1, CTLA4, LAG-3, and TIM-3 in the worst MS outcome (patients with high disability index, EDSS score of 6 in ≤5 years after diagnosis) to that of patients with mild MS (low disability index, EDSS score ≤1.5 at 10 years after diagnosis). This evidence concerns the gene TIGIT and myeloid sarcoma.